Mucous Membrane Pemphigoid Treatment Market Poised to Expand at a Robust Pace over 2018-2028
Mucous membrane pemphigoid is a group of rare and chronic autoimmune diseases which are characterized by blistering on the various mucous layers of the body. Mucous membranes of mouth, nose, throat, and eye are often affected by the mucous membrane pemphigoid. In June 2018, FDA approved Genentech's rituxan, first treatment in more than 60 years for the treatment moderate to severe pemphigus vulgaris (PV). The manufacturers in mucous membrane pemphigoid treatment market are focusing on the developing new and effective...
View full press release